SCHEMBL25166339

SCHEMBL25166339

CC(C)(C)OC(=O)Nc1cc(O)c2c(c1)NCCO2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.37
RET P07949 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA9 Q16790 1/20 0.36
PRKDC P78527 1/20 0.35
CYP17A1 P05093 3/20 0.34
EGLN2 Q96KS0 1/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ACHE P22303 1/20 0.34
BACE1 P56817 1/20 0.34
BRD4 O60885 2/20 0.33
CREBBP Q92793 2/20 0.33
PSMB8 P28062 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31107924 1.00 TRPV1 (0.37) TRPV1RETCA12CA1CA9
SCHEMBL25166337 0.80 HPGD (0.50) CA12CA1CA9PRKDCMEN1
SCHEMBL31107875 0.80 HPGD (0.50) CA12CA1CA9PRKDCMEN1
SCHEMBL31107949 0.80 BRD4 (0.41) TRPV1CA12CA1CA9KMT2A
SCHEMBL25166094 0.80 BRD4 (0.41) TRPV1CA12CA1CA9KMT2A
SCHEMBL25166560 0.79 ACHE (0.36) CA12CA1CA9PRKDCMEN1
SCHEMBL19648356 0.77 ALPL (0.37) TRPV1RETCA12CA1CA9
SCHEMBL25166367 0.74 NPC1 (0.42) CA12CA1CA9MEN1HPGD
SCHEMBL2229710 0.69 MEN1 (0.49) TRPV1CA12CA1CA9CYP17A1
SCHEMBL13175222 0.68 ATR (0.42) CA12CA1CA9CYP17A1EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 TRPV1 4868/4885RET 687/4885CA12 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.